Mandate

Vinge advises CMA Microdialysis in connection with the sale of pre-clinical business

July 04, 2011

Vinge has advised CMA Microdialysis in connection with the sale of its pre-clinical business to Harvard Biosciences. The main shareholders of MCA Microdialysis are Investor Growth Capital and Bure Equity. In connection with the transaction, the company has changed its name to Dipylon Medical.

Vinge’s team consisted of partner Johan Winnerblad together with, among others, fellow partner Fredrik Dahl and associate Claes Henriksson.

Related

Vinge advises Symrise on its public offer for Probi

Symrise AG has announced a public cash offer to the shareholders of Probi AB (publ) (“Probi”). The offer values Probi at approximately SEK 3,988 million. The shares in Probi are traded on Nasdaq Stockholm, Mid Cap.
November 20, 2024

Vinge advises Oxx in conjunction with an investment in Kodiak Hub

Kodiak Hub, a Swedish software as a service (SaaS) company, which offers its customers an AI-based software platform, has performed a capital procurement of EUR 6 million. The venture capital fund Oxx, which invests in SaaS companies, is the largest investor.
November 20, 2024

Vinge advises HAKI Safety AB (publ) in connection with the acquisition of Semmco Group Limited

Semmco Group is a UK market-leading manufacturer and supplier of maintenance platforms and stairs for aircraft and trains.
November 19, 2024